Fondaparinux Dosing in Renal Impairment

Contraindications and Precautions

The American College of Cardiology and other guideline societies contraindicate fondaparinux in patients with severe renal impairment (creatinine clearance <30 mL/min) due to increased risk of bleeding, with a strength of evidence level of high 1, 2
Fondaparinux should not be used in patients with end-stage renal disease or those on dialysis, with argatroban or danaparoid as preferred alternatives if anticoagulation is needed, based on moderate evidence 3
The drug's reliance on renal elimination with a prolonged half-life of 17-21 hours makes accumulation inevitable in severe renal dysfunction, contributing to the contraindication, with a strength of evidence level of high 4

For patients with normal renal function (CrCl >50 mL/min), the recommended dose for VTE prophylaxis is 2.5 mg subcutaneously once daily, with a strength of evidence level of high 1, 2
For VTE treatment in patients with normal renal function, weight-based dosing is recommended (5 mg if <50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg), based on low evidence 5
In moderate renal impairment (CrCl 30-50 mL/min), a reduced dose of 1.5 mg subcutaneously once daily is recommended, with a strength of evidence level of moderate 1

Unfractionated heparin (UFH) is the preferred alternative in patients with severe renal impairment (CrCl <30 mL/min) due to its hepatic metabolism, with a strength of evidence level of high 1, 4
Low molecular weight heparin (LMWH) can be used with caution in renal dysfunction, requiring dose adjustment and anti-Xa monitoring, based on moderate evidence 1
For dialysis patients with heparin-induced thrombocytopenia (HIT), argatroban or danaparoid are recommended over fondaparinux, with a strength of evidence level of high 3

For patients with moderate renal impairment (CrCl 30-50 mL/min), the European Heart Journal recommends reducing fondaparinux dose to 1.5 mg subcutaneously once daily for VTE prophylaxis, due to lower bleeding risk compared with enoxaparin 6
The European Society of Cardiology identifies fondaparinux as the drug of choice in moderate renal dysfunction (CrCl 30-60 mL/min) due to lower bleeding risk compared with enoxaparin 6

For NSTE-ACS patients with moderate renal impairment (CrCl 30-60 mL/min), fondaparinux may be considered due to lower bleeding risk compared with UFH plus GP IIb/IIIa inhibitors, according to the European Heart Journal 6
The American Heart Association recommends dose adjustment for fondaparinux in all ACS patients with renal impairment, and if fondaparinux is used during PCI, additional UFH (50-100 U/kg bolus) is required to prevent catheter thrombosis 7, 8
The American College of Cardiology advises against using fondaparinux in patients with creatinine >3 mg/dL when used with non-fibrin-specific thrombolytics 7, 8

The European Heart Journal warns against switching between fondaparinux and UFH or LMWH during treatment, as crossover increases bleeding risk 6

Fondaparinux is contraindicated when creatinine clearance is <30 mL/min due to the drug's complete renal elimination and prolonged half-life of 17-21 hours, which leads to inevitable drug accumulation and hemorrhagic risk, as recommended by the National Comprehensive Cancer Network 9
For STEMI patients receiving fibrinolytic therapy, fondaparinux is contraindicated if CrCl <30 mL/min, and the initial dose is 2.5 mg IV followed by 2.5 mg subcutaneously daily for up to 8 days or until revascularization, according to the American Heart Association, as published in Circulation 10

Elderly patients (>75 years) with moderate renal insufficiency require particular caution when using fondaparinux, as both age and renal dysfunction independently increase bleeding risk, as noted by the National Comprehensive Cancer Network 9